208 related articles for article (PubMed ID: 36629878)
1. Biodistribution and dosimetry for combined [
Delker A; Schleske M; Liubchenko G; Berg I; Zacherl MJ; Brendel M; Gildehaus FJ; Rumiantcev M; Resch S; Hürkamp K; Wenter V; Unterrainer LM; Bartenstein P; Ziegler SI; Beyer L; Böning G
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1280-1290. PubMed ID: 36629878
[TBL] [Abstract][Full Text] [Related]
2. An Intrapatient Dosimetry Comparison of
Rinscheid A; Gäble A; Wienand G; Pfob C; Dierks A; Kircher M; Trepel M; Weckermann D; Lapa C; Bundschuh RA
J Nucl Med; 2023 Dec; 64(12):1918-1924. PubMed ID: 37770108
[TBL] [Abstract][Full Text] [Related]
3. First-in-human study of
Zang J; Fan X; Wang H; Liu Q; Wang J; Li H; Li F; Jacobson O; Niu G; Zhu Z; Chen X
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):148-158. PubMed ID: 30090965
[TBL] [Abstract][Full Text] [Related]
4. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
5. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
6. Lesion Dosimetry for [
Grkovski M; O'Donoghue JA; Imber BS; Andl G; Tu C; Lafontaine D; Schwartz J; Thor M; Zelefsky MJ; Humm JL; Bodei L
J Nucl Med; 2023 Nov; 64(11):1779-1787. PubMed ID: 37652541
[TBL] [Abstract][Full Text] [Related]
7. Tandem Isotope Therapy with
Meyer C; Stuparu A; Lueckerath K; Calais J; Czernin J; Slavik R; Dahlbom M
J Nucl Med; 2023 Nov; 64(11):1772-1778. PubMed ID: 37797974
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract][Full Text] [Related]
9. Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study.
Kaur K; Nagi S; Satapathy S; Aggarwal P; Sood A; Mittal BR
Nucl Med Commun; 2024 Feb; 45(2):115-120. PubMed ID: 37982573
[TBL] [Abstract][Full Text] [Related]
10. [
Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of
Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120
[No Abstract] [Full Text] [Related]
12. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
13. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
14. Biodistribution and dosimetry of a single dose of albumin-binding ligand [
Kramer V; Fernández R; Lehnert W; Jiménez-Franco LD; Soza-Ried C; Eppard E; Ceballos M; Meckel M; Benešová M; Umbricht CA; Kluge A; Schibli R; Zhernosekov K; Amaral H; Müller C
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):893-903. PubMed ID: 32949253
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
16. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
18. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
20. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in
Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
Med Phys; 2019 Dec; 46(12):5861-5866. PubMed ID: 31587333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]